CTSO vs. SEPA, ICCM, LUCD, DRIO, APYX, XAIR, CTCX, DXR, LNSR, and HSAQ
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include SEP Acquisition (SEPA), IceCure Medical (ICCM), Lucid Diagnostics (LUCD), DarioHealth (DRIO), Apyx Medical (APYX), Beyond Air (XAIR), Carmell (CTCX), Daxor (DXR), LENSAR (LNSR), and Health Sciences Acquisitions Co. 2 (HSAQ). These companies are all part of the "surgical & medical instruments" industry.
SEP Acquisition (NASDAQ:SEPA) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.
Cytosorbents received 436 more outperform votes than SEP Acquisition when rated by MarketBeat users.
Cytosorbents has a consensus price target of $2.00, suggesting a potential upside of 127.30%. Given SEP Acquisition's higher possible upside, analysts plainly believe Cytosorbents is more favorable than SEP Acquisition.
In the previous week, Cytosorbents had 2 more articles in the media than SEP Acquisition. MarketBeat recorded 4 mentions for Cytosorbents and 2 mentions for SEP Acquisition. Cytosorbents' average media sentiment score of 1.88 beat SEP Acquisition's score of 0.07 indicating that SEP Acquisition is being referred to more favorably in the media.
SEP Acquisition has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.
3.7% of SEP Acquisition shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 20.0% of SEP Acquisition shares are held by insiders. Comparatively, 6.6% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
SEP Acquisition has a net margin of 0.00% compared to SEP Acquisition's net margin of -75.07%. Cytosorbents' return on equity of 0.00% beat SEP Acquisition's return on equity.
SEP Acquisition has higher earnings, but lower revenue than Cytosorbents.
Summary
Cytosorbents beats SEP Acquisition on 7 of the 13 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
